Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder with an estimated worldwide prevalence of up to ;1% in the adult population (1) . The root cause of disease is unknown, although both genetic and environmental factors play a role. The clinical hallmark of RA is an inflammatory arthritis with a predilection for diarthrodial joints (2) . Premenopausal women are at greater risk than men for developing RA (at a ratio of ;3:1) (1). While the disease can occur at any age, the peak age at disease onset is in the 40-50-year range, with an increasing incidence with age.
The genetic contribution to RA susceptibility in humans has been demonstrated convincingly through twin and family studies (3, 4) . It is estimated that ;60% of RA disease variability is inherited (3) . Whereas the population risk of RA is ;1%, the monozygotic twin of a patient with RA has a risk of ;15% (5-7). The major histocompatibility complex (MHC) region explains up to one-third of RA risk (8, 9) . Most of the risk attributable to the MHC region is associated with common alleles within the HLA-DRB1 gene-these are often referred to as "shared epitope" alleles (10, 11) -and the risk is increased only in anti-cyclic citrullinated peptide (anti-CCP)-positive patients with RA (in whom the odds ratio [OR] for RA is .5) (12,13). Genome-wide association studies (GWAS) have identified 100 non-MHC loci, which, together, explain an additional 5.5% of the RA heritability in Europeans and 4.7% of the RA heritability in Asians (14) .
Importantly, the genetic studies conducted to date have largely been restricted to patients of European or East Asian ancestry (14) . It is therefore unknown whether these same risk alleles contribute to the risk of RA among patients of Arab ancestry in the Middle East, or whether genetic studies in these populations might identify new loci for disease.
The purpose of our study was to investigate the cross-ethnic association of known European RA risk loci and to discover new RA risk loci in a multinational Arab case-control cohort. First, we hypothesized that common alleles identified from genetic studies of subjects of European ancestry will also contribute to the risk of RA among individuals of Arab ancestry, given that recent studies have shown that many risk alleles are shared among individuals of diverse ancestries (14, 15) . Second, we hypothesized that GWAS in an Arab population may point to novel RA risk loci of strong effect specific to Arab populations, similar to PADI1 variants in Asians (16) , or may indicate risk loci that have a higher allele frequency in Arabs relative to currently studied ethnic groups (as was found for a PTPN22 missense association in whites [17] ). Therefore, we enrolled RA patients and healthy controls in a genetic study of RA in a pan-Arab RA genetics consortium. We obtained measures of autoantibody status and performed genome-wide genotyping and a GWAS of RA, both in the entire population and in analyses stratified by ethnicity or autoantibody status.
PATIENTS AND METHODS
Subjects. A total of 794 RA patients and 573 healthy controls were included in this study. Subjects were enrolled from 5 centers in Jordan, the Kingdom of Saudi Arabia, Lebanon, Qatar, and the United Arab Emirates. To be eligible for the study, patients had to be of Arab ancestry (by self report), have RA diagnosed in accordance with the American College of Rheumatology 1987 criteria (18) , be $18 years of age, and be able to sign an informed consent. Controls eligible for enrollment in the study were healthy subjects free of autoimmune diseases. The controls were age-, sex-, and ethnicity-matched by frequency to the enrolled patients. Ethnicity was classified as self-reported African, Gulf, or Levant Arab ancestry.
Written informed consent was obtained from all subjects prior to enrollment in the study, in accordance with the Declaration of Helsinki for Human Studies, and the study was approved across all sites by the local Institutional Review Boards. In addition to age, sex, and self-reported ethnicity, we collected additional clinical information on the presence or absence of rheumatoid factor (RF) and anti-CCP antibodies, disease duration, medications used to treat RA, family history of RA, and vascular comorbidities (Table 1) .
Sample collection. For sample collection, 15 ml of whole blood was collected from each patient and each control subject in a prelabeled EDTA tube. Whole blood was then transferred into cryovials and stored at 2808C at each Rheumatology Center, and then batched-shipped to the Weill Cornell Medical College-Qatar for DNA extraction and storage. Samples were centrifuged so that buffy coat cells could be separated from plasma. Aliquots consisting of 1 ml buffy coat and 2 aliquots of up to 1 ml of plasma were created and stored at 2808C. DNA was extracted from the blood with a Gentra Puregene DNA extraction kit (Qiagen). An aliquot of the samples was sent to the Broad Institute for quality control and genome-wide genotyping. The DNA concentration was determined with a Quant-IT Picogreen double-stranded DNA reagent kit (Invitrogen). In total, 928 of the 937 samples had a sufficient concentration of DNA (.10 ng/ml) and sufficient yield of DNA for the GWAS. Thus, genome-wide genotyping of 922 samples was attempted. All 513 replication samples had a sufficient concentration of DNA (.10 ng/ml) for replication genotyping.
Genotyping and imputation in the discovery GWAS. In total, 922 samples were genotyped with a panel of ;30 singlenucleotide polymorphisms (SNPs) in the discovery GWAS, to create a molecular barcode for each sample. Genome-wide genotyping was performed at the Broad Institute in 2 batches (n 5 166 in batch 1 and n 5 756 in batch 2) using an Infinium HumanCoreExome Bead Chip array (Illumina). This array consists of 547,644 markers, with ;50% of the markers being selected to provide a GWAS scaffold for high-quality imputation and the other half being selected to provide coverage of lowfrequency, protein-altering variants identified from .12,000 worldwide sequences. Variant bases were called using the default Illumina GenCall algorithm. Subjects were removed from these analyses because of inbreeding (n 5 16), discrepancy in sex between the genetic and clinical data (n 5 3), duplicate samples (n 5 12), and cryptic relatedness (pi-hat .0.125, n 5 35), with 7 samples overlapping.
All samples had a genotyping rate of .90%. A total of 863 (93.6%) of the 922 samples passed the quality control review for the GWAS analysis. Only SNPs present at a frequency of $1% in the population were included in the GWAS. Of the 541,168 SNPs screened, 532,102 SNPs (98.3%) passed quality control. SNPs removed included 8,788 SNPs that were removed for having a call rate of ,95% or unmatched call rates in cases and controls, 450 SNPs that departed from Hardy-Weinberg equilibrium (P , 1.0 3 10
26
), and 172 SNPs that failed both tests. Imputation on clean genotypes was performed using the Impute 2 software package (19) and using the 1000 Genomes Phase 3 panel (May 2013). Postimputation quality control analyses filtered out variants with imputation quality information scores of ,0.88 and a minor allele frequency (MAF) of ,1%. After quality control, 7,000,653 SNPs in 511 cases and 352 controls were successfully tested for our discovery GWAS of Arab RA populations. HLA imputation was performed using SNP2HLA and the T1DGC European reference panel (20) .
Replication analysis. In total, 513 samples were genotyped for 23 SNPs in the replication analysis, using primer extension of multiplex products. SNPs were detected using matrixassisted laser desorption ionization-time-of-flight mass spectrometry with a Sequenom platform, as previously described (Broad Institute) (21) . Quality control steps excluded samples with a call rate of ,60% and SNPs with a call rate of ,95%, departure from Hardy-Weinberg equilibrium (P , 1.0 3 10
), or MAF of ,1%. Nineteen SNPs on 504 samples that passed quality control were available for replication association testing.
Assessment of population structure. To evaluate the population structure of this Middle-Eastern cohort relative to global populations, principal components (PCs) in the GWAS sample were calculated, prior to imputation, with the LASER: Locating Ancestry from SEquence Reads technique (22) , using 938 reference samples from the Human Genome Diversity Project (HGDP) (23) ( Figure 1A ). Clusters of individuals based on proximity to known HGDP samples in the PC analysis (PCA) were defined as either African-admixed (n5153) or non-African-admixed (n 5 700) Arab subgroups for secondary analyses ( Figure 1B) .
Statistical analysis. The GWAS were performed using logistic regression in SNPTEST (19) , with SNPs coded in an additive model and with adjustments for age, sex, and self-reported ancestry. Our discovery GWAS analysis comprised the entire case-control Arab population, and additional GWAS were performed in subpopulations stratified by seropositivity (seropositive RA, RF1/anti-CCP1 [n 5 357 cases, n 5 352 controls]; seronegative RA, RF2/anti-CCP2 [n 5 154 cases, n 5 352 controls]) or by ancestry (African-admixed Arabs, n 5 97 cases and n 5 56 controls; non-African-admixed Arabs, n 5 410 cases and n 5 290 controls). Genome-wide significance was considered at the Bonferroni-corrected threshold of P , 5.0 3 10 28 (24). Replication analysis was performed using logistic regression in Plink (25) , with SNPs coded additively and adjustments made for age, sex, and self-reported ancestry (African, Gulf, Levant). The threshold for statistical significance in the replication analysis was P , 0.003 (0.05 divided by 15). Association analysis of the imputed HLA variants in the MHC region was conducted as described elsewhere (26, 27) . Results from the discovery GWAS and replication analyses were combined in a fixed-effects metaanalysis with inverse variance weights, using METAL (28) .
We further calculated a cumulative aggregate genetic risk score (15) using the sum of the weighted risk allele counts for all previously known RA risk alleles that passed quality control in our current analysis (n 5 68 independent SNPs). The weights for each SNP were derived from the recently published meta-analysis of RA GWAS (14) and were calculated as the natural log of the OR for each allele. We determined the relationship between the genetic risk score and RA traits (29) . The level of statistical significance was considered at the Bonferronicorrected threshold of P , 0.0125 for 4 genetic risk score tests (0.05 divided by 4).
RESULTS
Genetic ancestries of the case-control Arab cohort. Results of PCA suggested that the group of individuals with self-reported African ancestry extended along a cline toward the HGDP Africans, while self-reported Gulf ancestry comprised ancestral components from African, Asian, and European populations, and self-reported Levant ancestry localized near the HGDP European populations ( Figure  1A ). Genetic ancestry allowed us to define 2 major subgroups of Arabs for secondary analyses: African-admixed (n 5 153) and non-African-admixed (n 5 700) ( Figure 1B ). Cases with African admixture (based on self-report or genetic ancestry) were more likely than non-African-admixed cases to be seropositive for RF and/or anti-CCP ( Table 2) .
Results of discovery and replication GWAS. In the discovery GWAS analysis of RA in the entire Arab case-control population, there was little inflation from undetected population structure or relatedness (l 5 1.044) (Figures 2A and B) and the estimated heritability ) in an intergenic region that was 789 kb from the nearest gene, CDH6 (Table 3 and Figure 3A) . A significant association with RA was also seen at rs9860428 on chromosome 3 (OR 1.64 [95% CI 1.33-2.04], P 5 6.24 3 10 26 ) ( Figure 3B ). GWAS analysis of subjects with seropositive RA (n 5 357 cases, n 5 352 controls) identified association signals at the HLA locus that were even stronger than those seen for RA overall (lead SNP, rs9269234 G allele; OR 2.51 [95% CI 1.98-3.19], P 5 4.86 3 10 214 ) ( Table 3 and Figure 4A ). Moreover, a novel signal at 17p13.2 was identified in seropositive RA subjects (lead SNP, rs12601925 G allele; OR 2.55 [95% CI 1.83-3.56], P 5 3.76 3 10 In the GWAS of ancestral subgroups, genomic inflation was only slightly lower than that in the GWAS analysis of RA overall (African-admixed Arabs, l 5 0.973; non-African-admixed Arabs, l 5 1.04) (see Supplementary Figures 1B and C, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40051/abstract). In the RA GWAS restricted to the smaller subgroup of subjects of African-admixed ancestry, no SNPs reached significance, whereas in the larger, more homogeneous non-African-admixed subgroup, the HLA locus remained significant (lead SNP, rs9269234 G allele; OR 2.00 [95% CI 1.57-2.54], P 5 1.87 3 10
28
) (see Supplementary Table 3 , http://onlinelibrary. wiley.com/doi/10.1002/art.40051/abstract).
Suggestive evidence of replication of significant SNPs at 4 of the 15 lead association signals was observed in an independent sample of 283 RA cases and 221 healthy Regional association plots of the genome-wide association study (GWAS) discovery results for the association of rheumatoid arthritis with single-nucleotide polymorphisms (SNPs) at chromosome 5 (Chr5) (A) and chromosome 3 (B). Analyses were adjusted for age, sex, and self-reported ancestry. Values are the 2log 10 P values of SNPs from the case-control GWAS plotted against the chromosomal position encompassing 400 kb around each lead SNP (purple): rs12519788 on chromosome 5 (A) and rs9860428 on chromosome 3 (B). The defined r 2 color scheme indicates the linkage disequilibrium (LD) relationship with the lead SNP. LD was calculated based on 1000 Genomes European population data. The recombination rate is shown in blue on the right. controls in our replication analysis (Table 3; see also Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40051/abstract). Notably, all 3 signals that reached genome-wide significance in the discovery GWAS (HLA-DRB1, 5q13, and 17p13) showed consistent allelic effects and remained genome-wide significant in the metaanalysis. A fourth signal, at 3q13.2, between the genes CD200R1 and CD200R1L, did not reach genome-wide significance in the discovery GWAS but showed evidence of replication after Bonferroni correction (P , 0.003). Furthermore, all 4 association signals showed consistent evidence of association in replication analyses restricted to cases with seropositive RA and all controls (Table 3 ). These signals explained 3.55% of the variability in risk of RA.
We cross-checked our results with regard to the lead SNPs at the 2 novel genome-wide significant signals at 5q13 and 17p13 in our Arab study population against the results of a recently reported transethnic metaanalysis of GWAS comprising subjects of East Asian and European ancestry (n 5 19,234 RA cases, n 5 61,565 controls) (14) . However, little evidence of association of these 2 signals with RA was observed in that study of East Asian and European subjects (for rs12519788 G allele, Genetic risk score of previously established RA loci in Arabs. We tested whether previously reported genome-wide significant RA associations from the transethnic meta-analysis previously conducted in East Asian and European populations (14) could be generalized to our Arab study population. Results for index SNPs at 68 of 101 non-HLA loci were available in our GWAS analyses (see Supplementary Table 4, available Imputation of HLA region amino acids and SNPs. In order to identify the SNPs and amino acids responsible for the HLA association signal, we performed HLA variant imputation in a manner as previously described (20) , using the European T1DGC reference panel, and tested for genetic association of imputed SNPs and amino acids with RA and with seropositive RA. Previous studies have suggested that 5 amino acids in 3 HLA proteins in the MHC account for most of the RA signal observed in individuals of European ancestry, and a common set of amino acid residues also confers risk in individuals of Asian ancestry, despite differences in traditional HLA alleles (26, 27) . Although we could not directly assess the imputation accuracy of the HLA variants in our study samples, previous studies have demonstrated the reliable accuracy of HLA imputation in multiple populations (26, 27) . Moreover, considering that HLA variants are known to have essential roles in RA according to seropositivity status, we assessed HLA variant risks separately in GWAS of subjects with seropositive RA and those with seronegative RA. In seropositive RA GWAS, amino acid position 11 in the gene HLA-DRB1 could account for the lead association signal (omnibus P 5 4.8 3 10
216
). In analyses conditioned on HLA-DRB1 amino acid position 11, no other HLA variants remained significant (P . 6.2 3 10
24
). We did not observe a significant association of HLA variants in the GWAS of subjects with seronegative RA (P . 3.6 3 10
).
DISCUSSION
Herein we report the first GWAS of RA in Arabs. First, we observed that known HLA and non-HLA RA risk loci observed in Europeans and East Asians are strongly associated with RA in our multinational Arab cohort. Consistently, we observed significant replication of the association of a specific HLA region amino acid with RA and with seropositive RA in this population. Second, we discovered 2 novel genomewide significant RA risk loci specific to Arab populations, with limited associations in other ethnicities.
In the last decade, genetic association studies in RA and meta-analyses of these associations have been helpful in uncovering novel risk alleles (14) . The majority of these studies have been performed in populations of European and East Asian ancestry, revealing some replication across different ethnicities while uncovering novel genetic risk factors (30) (31) (32) (33) . However, no genetic studies had been conducted in an Arab population to date.
The definition of Arab ancestry was based on selfreport, and all subjects studied were nationals of 1 of the 22 countries of the Arab world spanning from North Africa to the Arabian Gulf region, and categorized as 1 of 3 geographic Arab regions: Africa, Gulf, or Levant (as detailed in the League of Arab States web site at http:// www.lasportal.org/ar/Pages/default.aspx). As expected based on the multiple waves of migration that characterize Arab populations, our study population showed continental genetic heterogeneity, with genetic ancestry that distinguished African-admixed Arabs from nonAfrican-admixed Arabs. While these ancestral differences are large, we did not observe a significant effect of population stratification in the primary GWAS, most likely because within each ancestral group, cases and controls were well matched and our analyses included adjustment for ancestry.
Our hypothesis that common alleles identified from genetic studies of subjects of European ancestry also contribute to the risk of RA among individuals of Arab ancestry was validated in this study. GWAS of the entire RA case-control population showed a significant association within the HLA locus. This finding validates the importance of this region in RA susceptibility across different ethnic groups and confirms that our study is well powered to identify common alleles with large effect. The association was of larger magnitude and greater significance when the analysis was restricted to seropositive cases, as has been previously described.
Imputation of the HLA classic alleles and the HLA amino acid polymorphisms showed that HLA-DRB1 amino acid position 11 is the allele at the HLA locus most significantly associated with seropositive RA in Arabs, which is consistent with observations in European, Asian, and African-American populations (26, 27, 34) . In a study of Arab Syrians, DRB1 was found to be more common in RA patients compared to controls, and DRB1*0101, *0404, and *0405 had a stronger association with joint destruction (35) . Similarly, a strong association of a genetic risk score of 68 known RA loci was observed in our Arab population, again confirming that a majority of RA risk loci are consistently associated across multiple ethnic groups.
Second, we hypothesized that GWAS in an Arab population may point to novel RA risk loci of strong effect specific to Arab populations. Two loci that have not been previously reported in European or East Asian RA GWAS reached statistical significance in our study, consistent with the notion of strong population-specific effects, as was also previously seen for the PADI1 locus in Asians. The locus at 5q13 was detected in the entire case-control study, and the locus at 17p13 was identified in the seropositive RA subgroup. Replication of these findings in independent Arab samples suggests that the causal SNPs underlying these association signals are likely to play an important role in the risk of RA in the Arab population.
The lead SNP at the novel 5q13 signal lies in an intergenic region flanked by the calcium-dependent cellcell adhesion gene CDH6 ;789 kb upstream and the gene encoding the 7SK small nuclear RNA controlling transcriptional elongation ;456 kb downstream (36) . The CDH6 gene encodes K-cadherin, which has previously been implicated in adhesion between immune cells (37), has been described as a tumor suppressor (38) , and has been found to be significantly down-regulated in a rat model of arthritis (39) . The 7SK small nuclear RNA has also been implicated in cancer (40) and HIV latency (41), but not in autoimmunity. The lead SNP at the 17p13 locus lies in an intron of the smoothelin-like gene SMTNL2, which is implicated in a region defined by epigenetic marks for promoters and enhancers as well as DNase 1 hypersensitivity sites across many tissues (42) . However, whether this regulatory region influences this gene or neighboring genes, e.g., ALOX15 or GGT6, among several, will require future studies. SMTNL2 is exclusively expressed in skeletal muscle (43) , while ALOX15 and GGT have previously been implicated in RA inflammatory processes (44, 45) .
A fourth association signal at 3q13.2 near CD200R1, encoding the CD200 receptor (CD200R), almost reached significance after replication. The CD200-CD200R axis has previously been demonstrated to be important in autoimmunity, both in humans and in mice, with a potential role in Th17 cell differentiation, chemotaxis, and osteoclastogenesis in RA (46) . A soluble ligand of CD200R has been investigated in preclinical models as a therapeutic agent for RA (47) .
Our cross-check investigation of the 2 novel signals (5q13 and 17p13) against a large transethnic meta-analysis of subjects of East Asian and European ancestry suggests that these Arab-specific loci may not be relevant in the other 2 ethnicities, although the alleles themselves are quite common in all ethnic groups. The frequency of the risk allele of the lead SNP at 17p13 varies between studies and was found to be highest in our Arab cohort (frequency of the G allele, 0.86 in Arabs [present study], 0.83 in Europeans, and 0.40 in East Asians), whereas the risk allele frequency at 5q13 was more similar, yet still highest in Arabs (frequency of the G allele, 0.79 in Arabs [present study], 0.66 in Europeans, and 0.78 in East Asians). Thus, we expect that these loci have a population-specific effect in Arabs, and associated SNPs may tag as-yet-undetected novel variations in Arab populations that might have arisen after divergence from other populations. Notably, we did detect consistent effects at these loci in both non-Africanadmixed and African-admixed Arab populations.
RA risk loci tend to demonstrate pleiotropy with other human phenotypes, including immune-related diseases. However, this was not the case for the novel loci identified in this GWAS (17p13, 5q13, and 3q13.2). It might be that these loci are Arab-specific with limited relevance to other ethnicities, and as a result, have not been associated with other diseases. With that said, unraveling these ethnicity-specific loci is only possible by conducting these transethnic GWAS for RA.
Earlier investigations have suggested that the genetic architecture of seropositive RA and seronegative RA is different, and also that few genetic markers, including the HLA locus, may or may not be associated with seronegative RA (48) . Our analyses have not pointed to other loci that predict seronegative RA, likely because of the heterogeneity in phenotype, low heritability, and high polygenicity of the trait, as well as the low statistical power of our study. It is highly possible that multiple undiscovered loci remain to be determined.
Strengths of our study include the large pan-Arab case-control population, implementation of careful technical and analytic quality control measures across our study population, as demonstrated by low inflation values and validation of known associations, and discovery and confirmation of novel associations that may be specific to Arab populations and other related populations. Weaknesses of the study include the lack of a central laboratory to test for RF and anti-CCP status in a standardized manner, possibly resulting in underestimation of the number of seropositive cases. In addition, data on anti-CCP status were missing from 1 of the countries due to financial restrictions, and radiographic data as well as data on disease severity or response to medication were lacking. Finally, there was insufficient power to detect associations with seronegative RA, and a European reference panel was used for HLA imputation.
In summary, our study findings establish that the HLA region, previous RA risk alleles identified in European and Asian populations, and novel Arab-specific loci play a causal role in RA and in seropositive disease in the Arab population. Larger studies using genome-wide approaches are now needed to validate population-specific alleles and to more fully characterize the genes and pathways involved in RA pathogenesis and severity in Arab populations.
